| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 370 | 2021 |
| NCCN guidelines® insights: B-cell lymphomas, version 5.2021: featured updates to the NCCN guidelines AD Zelenetz, LI Gordon, JE Chang, B Christian, JS Abramson, RH Advani, ... Journal of the National Comprehensive Cancer Network 19 (11), 1218-1230, 2021 | 119 | 2021 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 113 | 2020 |
| Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... New England Journal of Medicine 389 (1), 33-44, 2023 | 67 | 2023 |
| Bones in multiple myeloma: imaging and therapy E Zamagni, M Cavo, B Fakhri, R Vij, D Roodman American Society of Clinical Oncology Educational Book 38, 638-646, 2018 | 49 | 2018 |
| Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma BT Hill, L Nastoupil, AM Winter, MR Becnel, JR Cerhan, TM Habermann, ... British journal of haematology 184 (4), 524-535, 2019 | 45 | 2019 |
| Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies B Fakhri, MA Fiala, SA Tuchman, TM Wildes Clinical Lymphoma Myeloma and Leukemia 18 (3), 219-224, 2018 | 45 | 2018 |
| Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study T Siddiqi, DG Maloney, SS Kenderian, DM Brander, K Dorritie, ... The Lancet 402 (10402), 641-654, 2023 | 38 | 2023 |
| LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL/SLL: results from the phase 1/2 BRUIN study AR Mato, JM Pagel, CC Coombs, NN Shah, N Lamanna, E Lech-Marańda, ... Blood 136, 35-37, 2020 | 34 | 2020 |
| Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure EC Ayers, S Li, LJ Medeiros, DA Bond, KJ Maddocks, P Torka, ... Cancer 126 (2), 293-303, 2020 | 32 | 2020 |
| Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER‐Medicare database B Fakhri, MA Fiala, N Shah, R Vij, TM Wildes Cancer 126 (4), 808-813, 2020 | 31 | 2020 |
| Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature B Fakhri, KH Lim Journal of Gastrointestinal Oncology 8 (3), 379, 2017 | 31 | 2017 |
| Halfway there: the past, present and future of haploidentical transplantation M Slade, B Fakhri, BN Savani, R Romee Bone Marrow Transplantation 52 (1), 1-6, 2017 | 30 | 2017 |
| Clonal evolution in multiple myeloma B Fakhri, R Vij Clinical Lymphoma Myeloma and Leukemia 16, S130-S134, 2016 | 29 | 2016 |
| Current and emerging treatment options for mantle cell lymphoma B Fakhri, B Kahl Therapeutic Advances in Hematology 8 (8), 223-234, 2017 | 27 | 2017 |
| LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenström’s macroglobulinemia, and other non-hodgkin … M Wang, NN Shah, AJ Alencar, JN Gerson, MR Patel, B Fakhri, W Jurczak, ... Blood 136, 8-10, 2020 | 24 | 2020 |
| Current and emerging treatment options in primary mediastinal B-cell lymphoma B Fakhri, W Ai Therapeutic Advances in Hematology 12, 20406207211048959, 2021 | 22 | 2021 |
| Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenström macroglobulinemia: results from the phase 1/2 BRUIN study ML Palomba, MR Patel, TA Eyre, W Jurczak, DJ Lewis, T Gastinne, S Ma, ... Blood 140 (Supplement 1), 557-560, 2022 | 21 | 2022 |
| Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: additional patients and extended follow-up from the phase 1/2 BRUIN study AR Mato, JA Woyach, JR Brown, P Ghia, K Patel, TA Eyre, T Munir, ... Blood 140 (Supplement 1), 2316-2320, 2022 | 21 | 2022 |
| Immune-related adverse events associated with checkpoint inhibition in the setting of CAR T cell therapy: a case series S Kambhampati, L Gray, B Fakhri, M Lo, K Vu, S Arora, L Kaplan, WZ Ai, ... Clinical Lymphoma Myeloma and Leukemia 20 (3), e118-e123, 2020 | 20 | 2020 |
